NCT01267578

Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II)

Phase II Multicenter Trial of Peptide Vaccination Therapy Using Novel Cancer Testis Antigens (STF-II) for Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: University of Yamanashi · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate overall survival and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens (STF-II) for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma

Detailed description

The phase II multicenter trial of vaccination study using peptides derived from URLC10, CDCA1, and KOC1 for locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) who had failed for the standard therapy are performed to evaluate the survival benefit of the cancer vaccination.

Conditions

• Esophageal Cancer

Interventions

Type	Name	Description
BIOLOGICAL	vaccination	Biological/Vaccine: URLC10, CDCA1, and KOC1 peptides

Timeline

• Start date: 2010-04-01
• Primary completion: 2011-05-01
• Completion: 2012-05-01
• First posted: 2010-12-28
• Last updated: 2010-12-28

Locations

1 site across 1 country: Japan